12:25 PM EST - Optimi Health : Announced that it has completed the acquisition of a diverse catalog of psilocybin and functional mushroom strains intended for cultivation in its 20,000 square foot, EU-GMP compliant facility in Princeton, British Columbia. The Company’s acquisition includes 24 psychedelic and nine functional strains, giving it one of the largest genetic banks in the sector. Formulated psychedelic strains will be made available to licensed researchers, Canada’s Special Access Program, as well as being utilized for on-site research in Optimi’s analytical laboratory, while the functional strains will be optimized for the Company’s natural supplement brand, Optimi Life. Optimi Health
shares C.OPTI are trading up one cent at $0.26.
